About the Corporate Council
The ACAAI Corporate Council offers companies exposure to nearly 6,000 allergists and immunologists, including more than 3,000 who are board-certified by the ABAI. Participation in the Corporate Council also provides valuable access to the ACAAI Board of Regents and other key opinion leaders.
The Corporate Council is comprised of senior executives from pharmaceutical, medical device and other companies involved in the field of allergy and immunology. Two representatives from each participating company will hold seats on the Corporate Council and will be invited to the annual Corporate Council roundtable meeting.
The Council’s goal is to address critical issues in allergy and immunology, find solutions to pressing challenges, share knowledge of best practices and advise members on upcoming initiatives. By pooling resources and expertise, Corporate Council members and the ACAAI leadership can engage in joint problem-solving and explore collaborative opportunities to improve patient care and advance the mission of ACAAI.
To learn more about becoming a member of the ACAAI Corporate Council, please contact:
Director of Corporate Relations
American College of Allergy, Asthma & Immunology
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for patients with food allergies. Aimmune was formed by leading food allergy stakeholders who concluded that a standardized oral immunotherapy approach was needed and that associated therapies needed to be developed. To deliver on that purpose, Aimmune developed the Characterized Oral Desensitization ImmunoTherapy (CODIT®) approach, which is intended to mitigate allergic reactions from accidental exposure to food allergens. Aimmune is the first company to have an FDA-approved treatment for any food allergy and is applying the CODIT approach to investigate additional food allergy therapies. Please visit www.aimmune.com .
As the World Leader in Allergy Immunotherapy (AIT), the only treatment that treats the underlying cause of allergic disease, ALK is devoted to improving the quality of life for people with allergies by offering more convenient methods of administration, and thereby expanding the overall use of AIT to more patients. We are committed to broadening our presence in allergy care and will continue to innovate, develop, and market new solutions beyond AIT, that bring us closer to allergic patients. Our goal is to build an effective future growth platform to engage with allergic patients and connect them will Allergy Specialists earlier in the disease progression.
At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases. Amgen believes the cure for disease can be found inside each and every one of us.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca-us.com.
DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV’s Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
111 Virginia Street, Suite 300
Richmond, VA 23219
kaléo is a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions.
Optinose is a specialty pharmaceutical company focused on creating and bringing to market innovative products for patients with diseases treated by ear, nose, and throat (ENT) and allergy specialists. Our mission is to improve the quality of life for patients. We will accomplish that by becoming the leading specialty pharmaceutical company dedicated to creating innovative products that become standard of care for diseases cared for directly by, or in consultation with, ENT and allergy specialists.
Pharming Healthcare, Inc. is dedicated to providing life-changing solutions to patients. Pharming is currently involved in the development of drugs for the treatment of hereditary angioedema and has marketing operations in the United States, Israel, all 28 European Union countries plus Norway, Iceland, and Liechtenstein.
Sanofi Genzyme and Regeneron are committed to providing resources to advance education and research in areas of unmet medical needs among patients with inflammatory and immunological diseases.
Takeda Pharmaceutical Company Limited
650 Kendall Street
Cambridge, MA 02142
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit www.takeda.com.